This target was of particular interest, first due to its role in MAPK signaling, a crucial pathway in thyroid cancer, and in addition, our group had previously identified SPRY4 as a novel candidate susceptibility gene for familial nonmedullary thyroid cancer (FNMTC) [45]. The gene discussed is SPRY4; the disease is thyroid gland carcinoma.